This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Herberg, L.J. Articles by Grottick, A.J. Search for Related Content PubMed Articles by Herberg, L.J. Articles by Grottick, A.J. Social Bookmarking                         What's this?

2-Adrenoreceptor antagonism may contribute to the atypical properties of risperidone: experimental support for the Nutt case

Institute of Neurology, Queen Square, London WC1N 3BG

A.M.J. Montgomery

Department of Psychology, London Guildhall University, London, UK

A.J. Grottick

Institute of Neurology, Queen Square, London WC1N 3BG, Department of Psychology, London Guildhall University, London, UK

The therapeutic efficacy and reduction in side effects claimed for new antischizophrenic drugs such as clozapine and risperidone have been ascribed to their heightened affinity for serotonin 5-HT₂ receptors rather than D-2 receptors. A case for ₂-adrenoreceptor antagonism has recently been argued. We have confirmed that at least one atypical property of risperidone (a rapid decrement in its ability to depress self-stimulation) can be partly prevented by an ₂-adrenoreceptor agonist (clonidine) but not by a 5-HT ₂ receptor agonist (DOI). This result supports the suggested role of ₂-adrenoreceptor antagonism in counteracting extrapyramidal effects during treatment with risperidone.

Key Words: 2-adrenoreceptors • atypical neuroleptics • clonidine • clozapine • DOI • risperidone • self-stimulation

Journal of Psychopharmacology, Vol. 9, No. 3, 281-283 (1995)
DOI: 10.1177/026988119500900312


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?